About Cancer Prevention Pharmaceuticals, Inc. Cancer Prevention Pharmaceuticals, Inc. is developing therapeutics designed to reduce the risk of cancer and other diseases. Our Product Pipeline includes pharmaco-prevention therapies to address GI cancers, pediatric cancers and early-onset type 1 diabetes. Our innovative technology addresses polyamine synthesis and inflammation to reduce cancer risk. These two processes have long been implicated in cancer development but never successfully utilized together to exploit and treat cancer precursors until now. In partnership with Mallinckrodt Plc., CPP is sponsoring the FAP-310 Pivotal Phase 3 Trial of our lead product, CPP-1X/sul, for Familial Adenomatous Polyposis (FAP). CPP-1X/sul has been granted “Fast Track” and “Orphan Drug” designation from the Food and Drug Administration (FDA). Trial results are expected in early 2019. With the National Cancer Institute (NCI) and SWOG, CPP is co-sponsoring the PACES Phase 3 Trial of CPP-1X/sul for colon cancer survivors. PACES is the largest and longest-running trial ever conducted in colon cancer survivors and is currently recruiting participants. CPP is also working collaboratively with research institutions and nonprofit groups in support of their clinical trials in neuroblastoma, gastric cancer and early-onset type 1 diabetes. CPP was founded by some of the most highly respected leaders in preclinical and clinical cancer prevention research. We work closely with the National Cancer Institute (NCI), FDA, and the European Medicines Agency (EMA) to make prevention therapies a reality for those at risk for cancer. We are headquartered in Tucson, Arizona.